BMA chairman warns reforms add to threat of ‘two-tier NHS’
April 26, 2004The chairman of the BMA has warned that new reforms are adding to the threat of a two-tier NHS posed …
US legal action Aventis’ latest weapon in repelling Sanofi
April 26, 2004Aventis has unleashed its latest stratagem in resisting Sanofi-Synthleabo's hostile takeover bid, a US legal action claiming its rival has …
A tale of two pills for Pfizer in Q1
April 26, 2004Pfizer, torceptrapib
The first quarter of 2004 saw Pfizer’s biggest seller Lipitor extend its domination of the statin market but Viagra, another …
Aventis’ Apidra approved in US
April 26, 2004The FDA has approved Aventis' rapid-acting insulin analogue Apidra, ahead of an anticipated August approval by the EMEA, as the …
No change one year on from NSF, says diabetes charity
April 26, 2004One year on from the launch of the National Service Framework (NSF) for Diabetes, the planning of care has improved …
Wyeth’s Zoton hot on the heels of over-the-counter Zanprol
April 26, 2004Wyeth, manufacturers of the UK's biggest selling prescription drug Zoton plan to take the drug POM-P, hot on the heels …
The brave new GMS world
April 26, 2004The new General Medical Services contract (nGMS) started officially on 1st April, though its far-reaching effects may be far from …
Supporting the everyday experts
April 26, 2004We are all familiar with the growth of the ageing population during the second half of the 20th century and …
Sanofi slims down portfolio in preparation for Aventis acquisition
April 15, 2004Sanofi-Synthelabo has agreed to sell two of its products to GlaxoSmithKline, as it seeks to avoid potential problems with competition …
Britannia and Otsuka collaborate on autoimmune disease treatment
April 15, 2004Britannia Pharmaceuticals has entered into an agreement with Otsuka Pharmaceuticals UK to manage the UK distribution of the novel treatment …
Heart concerns halt Acambis trials
April 15, 2004UK biotech Acambis has suspended Phase III clinical trials of its smallpox vaccine after three patients suffered a heart inflammation …
Avastin gets off to a flying start
April 15, 2004US biotech Genentech's first quarter results have surpassed estimates as the company posted profit growth of 17% to $176.6 million, …
Giving patients more choice
April 15, 2004You might be forgiven for having missed the launch of Labour's new policy statement on patient choice, Building on the …
Aventis invites Novartis ‘white knight’ bid
April 7, 2004Aventis has formally invited Swiss rival Novartis into merger talks, but still needs to convince the French government of the …
Lilly’s ‘Le Weekender’ gaining ground on Viagra
April 7, 2004Eli Lilly's Cialis is rapidly winning market share from Viagra, Pfizer's trailblazing erectile dysfunction (ED) drug, which is now starting …
Another April revolution to transform the NHS
April 7, 2004For the second time in three years, the National Health Service has undergone an April revolution through the major re-engineering …
Crestor hits ‘a bump in the road’ as BMS study backfires
April 6, 2004AstraZeneca's Crestor has suffered a setback in the US as its share in the highly competitive statin market fell back …
